Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
-
BUSINESS Sanofi Files Sarclisa as 1st-Line Quad Therapy for MM in Japan
May 15, 2024
-
BUSINESS Seikagaku’s Herniated Disk Drug Accepted for US FDA Review
May 15, 2024
-
BUSINESS Sumitomo Pharma to Kick Off PI Study for Universal Flu Vaccine in Europe
May 15, 2024
-
BUSINESS Sumitomo Seeks Label Expansion for Gemtesa in US
May 15, 2024
-
REGULATORY Japan Will Hew to 4-Minister Pact on Off-Year Revisions: Health Minister
May 15, 2024
-
BUSINESS Takeda, AC Immune Sign US$2 Billion Alzheimer’s Deal
May 14, 2024
-
BUSINESS Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
-
BUSINESS Shionogi’s COVID-19 Pill Fails to Show Significant Difference in Global PIII
May 14, 2024
-
BUSINESS Blackstone to Take I’rom Group Private in Bid to Address Japan’s Drug Lag
May 14, 2024
-
REGULATORY Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
-
BUSINESS Suzuken Eyes One-Stop Platform for Japan Launch of “Loss” Products
May 14, 2024
-
BUSINESS Fycompa Approved for Label Expansion in China: Eisai
May 14, 2024
-
BUSINESS Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
May 14, 2024
-
ACADEMIA Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
-
BUSINESS Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
-
REGULATORY Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
-
REGULATORY Posaconazole Added to List of Azole Antifungals Contraindicated for Xarelto on Bleeding Risks
May 13, 2024
-
BUSINESS Sumitomo Splits Non-Pharma “Frontier” Business
May 13, 2024
-
REGULATORY Shionogi COVID Jab Up for PAFSC Review Again after Efficacy Questions; Pfizer’s Zavicefta and Lots More on Roster
May 13, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…